Why developing new antibiotics is a matter of life and death
Antibiotic-resistant superbugs kill 700,000 people worldwide each year, but what's stopping the development of new treatments?
Kasim Kutay
Chief Executive Officer, Novo Holdings
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:
Healthcare Delivery
License and Republishing
World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.
The views expressed in this article are those of the author alone and not the World Economic Forum.
Global Agenda
The Agenda Weekly
A weekly update of the most important issues driving the global agenda
Subscribe
You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.
More on Healthcare DeliverySee all
More on Healthcare Delivery
See all
